Target type: biologicalprocess
Any process that decreases the frequency, rate or extent of the chemical reactions and pathways resulting in the phosphorylation of ADP to ATP that accompanies the oxidation of a metabolite through the operation of the respiratory chain. Oxidation of compounds establishes a proton gradient across the membrane, providing the energy for ATP synthesis. [GOC:BHF]
Negative regulation of oxidative phosphorylation is a complex biological process that involves a multitude of regulatory mechanisms to control the rate of ATP production through the electron transport chain. This process is crucial for maintaining cellular energy homeostasis and preventing oxidative stress. Key mechanisms involved in negative regulation include:
1. **Regulation of Electron Transport Chain Complexes:**
- **Inhibition of Complex I (NADH dehydrogenase):**
- **Rotenone:** A potent inhibitor of Complex I, blocking electron transfer from NADH to ubiquinone.
- **Amytal:** Another inhibitor of Complex I, acting at a different site than rotenone.
- **Inhibition of Complex III (cytochrome bc1 complex):**
- **Antimycin A:** Blocks electron flow from ubiquinol to cytochrome c.
- **Inhibition of Complex IV (cytochrome c oxidase):**
- **Cyanide:** Binds to the heme iron in cytochrome a3, preventing oxygen reduction.
- **Carbon monoxide:** Binds to the heme iron in cytochrome a3, blocking oxygen reduction.
- **Azide:** Binds to the heme iron in cytochrome a3, blocking oxygen reduction.
2. **Regulation of Proton Gradient:**
- **Uncoupling Agents:**
- **2,4-dinitrophenol (DNP):** Dissipates the proton gradient across the inner mitochondrial membrane, reducing ATP synthesis.
- **FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone):** A protonophore that carries protons across the mitochondrial membrane, uncoupling ATP synthesis from electron transport.
3. **Regulation of Substrate Availability:**
- **NADH/NAD+ Ratio:**
- High NADH/NAD+ ratio can inhibit Complex I activity, reducing electron flow through the chain.
- **ADP/ATP Ratio:**
- High ATP levels can feedback inhibit oxidative phosphorylation by reducing the availability of ADP, a necessary substrate for ATP synthesis.
4. **Regulation by Cellular Signaling Pathways:**
- **AMPK (AMP-activated protein kinase):**
- Activated by low cellular energy levels (high AMP/ATP ratio), AMPK inhibits oxidative phosphorylation to conserve energy.
- **Reactive Oxygen Species (ROS):**
- High levels of ROS can activate signaling pathways that negatively regulate oxidative phosphorylation.
5. **Regulation by Protein Modifications:**
- **Phosphorylation:**
- Phosphorylation of specific proteins involved in oxidative phosphorylation can alter their activity.
- **Acetylation:**
- Acetylation of specific proteins can also regulate their activity.
6. **Regulation by Gene Expression:**
- Transcription factors can regulate the expression of genes encoding proteins involved in oxidative phosphorylation.
Negative regulation of oxidative phosphorylation is a complex and dynamic process, and its dysregulation can contribute to various pathological conditions, including cancer, neurodegenerative diseases, and aging. Understanding the mechanisms involved in this process is crucial for developing therapeutic strategies for these diseases.
'"
Protein | Definition | Taxonomy |
---|---|---|
Transforming protein RhoA | A GTP-binding protein RhoA that is encoded in the genome of human. [PRO:CNA, UniProtKB:P61586] | Homo sapiens (human) |
Peptidyl-prolyl cis-trans isomerase F, mitochondrial | A peptidyl-prolyl cis-trans isomerase F, mitochondrial that is encoded in the genome of human. [PRO:DNx, UniProtKB:P30405] | Homo sapiens (human) |
Tumor necrosis factor | A tumor necrosis factor that is encoded in the genome of human. [PRO:DNx] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
mesalamine | mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position. Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed) | amino acid; aromatic amine; monocarboxylic acid; monohydroxybenzoic acid; phenols | non-steroidal anti-inflammatory drug |
way 151693 | |||
pentoxifylline | oxopurine | ||
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone | 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone: Inhibitor of phosphodiesterases. | methoxybenzenes | |
rolipram | pyrrolidin-2-ones | antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor | |
sulfasalazine | sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position. Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907) | ||
bergenin | bergenin: RN refers to (2R-(2alpha,3beta,4alpha,4aalpha,10bbeta))-isomer; structure | trihydroxybenzoic acid | metabolite |
marimastat | marimastat : A secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide. marimastat: a matrix metalloproteinase inhibitor active in patients with advanced carcinoma of the pancreas, prostate, or ovary | hydroxamic acid; secondary carboxamide | antineoplastic agent; matrix metalloproteinase inhibitor |
birb 796 | aromatic ether; morpholines; naphthalenes; pyrazoles; ureas | EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; immunomodulator | |
ganoderic acid a | triterpenoid | ||
ganoderiol f | ganoderiol F: a ganoderma triterpene from Ganoderma amboinense; structure in first source | triterpenoid | |
1-(phenylmethyl)benzimidazole | benzimidazoles | ||
luteolin-7-glucoside | luteolin 7-O-beta-D-glucoside : A glycosyloxyflavone that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage. luteolin-7-glucoside: has both antiasthmatic and antineoplastic activities; has 3C protease inhibitory activity; isolated from Ligustrum lucidum | beta-D-glucoside; glycosyloxyflavone; monosaccharide derivative; trihydroxyflavone | antioxidant; plant metabolite |
apigetrin | apigenin 7-O-beta-D-glucoside : A glycosyloxyflavone that is apigenin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage. apigetrin: structure given in first source | beta-D-glucoside; dihydroxyflavone; glycosyloxyflavone; monosaccharide derivative | antibacterial agent; metabolite; non-steroidal anti-inflammatory drug |
calycosin-7-o-beta-d-glucopyranoside | calycosin-7-O-beta-D-glucoside : A glycosyloxyisoflavone that is calycosin substituted by a beta-D-glucopyranosyl residue at position at 7 via a glycosidic linkage. calycosin-7-O-beta-D-glucoside: from Radix Astragali | 4'-methoxyisoflavones; 7-hydroxyisoflavones 7-O-beta-D-glucoside; hydroxyisoflavone; monosaccharide derivative | |
spd-304 | SPD-304: structure in first source | ||
(melle-4)cyclosporin | (melle-4)cyclosporin: a non-immunosuppressive analog of cyclosporin A | ||
scy-635 | |||
alisporivir | alisporivir: nonimmunosuppressive cyclosporin analog; structure/sequence in first source | homodetic cyclic peptide | anticoronaviral agent |
ganoderic acid f | ganoderic acid F: isolated from Ganoderma lucidum; structure in first source | triterpenoid | |
ganoderic acid c2 | ganoderic acid C2: from the fruiting body of Ganoderma; structure in first source | triterpenoid | |
ccg-203971 |